Document:

EX-10.29

 Exhibit 10.29 

TECHNOLOGY EVALUATION AND 

MASTER DEVELOPMENT AGREEMENT 

This Technology Evaluation and Master Development Agreement (the “Agreement”) is made as of the 13th day of
September, 2011 (the “Effective Date”) by and between The Scotts Company LLC, an Ohio limited liability company, having its principal place of business at 14111 Scottslawn Road, Marysville, Ohio 43041, U.S.A.
(“Scotts”), and Marrone Bio Innovations, Inc., a Delaware corporation, having its principal place of business at 2121 Second Street, Suite 107B, Davis, California 95618, U.S.A. (“MBI”). Each of Scotts and MBI is
sometimes individually referred to as a “Party” and collectively referred to as the “Parties”. 

WHEREAS, Scotts is a leading provider of high-quality branded consumer lawn, garden, and household pest control
products and services. 
 WHEREAS, MBI is a leading innovator that discovers, develops, and markets effective and
environmentally responsible natural products that focus on unmet needs for weed, pest, and plant disease management. 

WHEREAS, the Parties desire to enter into this Agreement, under which MBI grants to Scotts certain rights in the
Consumer Market (defined below) to the MBI Technology Portfolio (defined below) so that Scotts may evaluate the MBI Technology Portfolio for potential commercialization by Scotts in the Consumer Market; and, in furtherance thereof, the Parties may
undertake, as applicable, certain collaborative development activities under one or more Development Projects (defined below) as detailed in a corresponding Project Plan (defined below), each Project Plan being an addendum to this Agreement and
incorporated herein by reference. 
 NOW, THEREFORE, in consideration of the foregoing, the mutual agreements,
covenants and promises contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

Article 1. 
 STRUCTURE;
DEFINITIONS 
 1.1 Agreement Components. The Parties intend to negotiate and potentially enter into
one or more related agreements in the form of addenda to this Agreement (each of such executed addenda shall be referred to as a “Project Plan”), and such Project Plans, if entered into, will incorporate the terms of this Agreement
and will be incorporated herein by reference subject to the terms and conditions hereof. 
 1.2
Conflicts. In the event of a conflict between this Agreement and a Project Plan, the terms of this Agreement shall govern unless an individual Project Plan expressly and specifically notes the deviations from the terms of this
Agreement. 

  
 1 

 1.3    Definitions. The capitalized
terms set forth below shall have the meanings indicated. Other capitalized terms defined elsewhere in this Agreement shall have the meaning ascribed to such terms when capitalized. 

1.3.1    “Ag Market” shall mean the market(s) for direct or indirect sale or provision
of pest and weed control or plant disease management products or services for use in commercial agriculture, including but not limited to applications for foliar, soil, root, seed, plant health, plant protection and/or fertility, and also including
without limitation commercial turf and ornamental markets. 
 1.3.2    “Aquatic
Market” shall mean the market(s) for direct or indirect sale or provision of aquatic pest control products or services for use in non-residential and non-individual consumer applications, including but not limited to applications in
industrial plants, power generation plants, open water, lakes and lake associations, fisheries, golf courses and ballast or containment treatments. 

1.3.3    “Background IP” shall mean any improvement, device, prototype, product, active
ingredient, formulation, apparatus, system, method, process, technique, invention, know-how, Trade Secret, Confidential Information, or other technical, industrial, or intellectual property, for which the Intellectual Property Rights became owned or
licensed by a Party prior to the Effective Date of this Agreement, or, outside the scope of any Development Project if after the Effective Date of this Agreement, whether protectable or not in the United States or abroad by Intellectual Property
Rights. 
 1.3.4    “Commercial Supply and License Agreement” shall have the meaning
attributed to it in Section 5.1 hereof. 
 1.3.5    “Confidential Information”
shall have the meaning attributed to it in Section 7.1 hereof. 
 1.3.6    “Consumer
Market” shall mean the market(s) for direct or indirect sale or provision of consumer lawn, garden, and outdoor living products, including, without limitation, plants, flowers, trees and shrubs, fertilizer, fertilizer combination products,
seed, growing media (including, without limitation, peat and/or coir products, soil conditioning agents, turf dressings, compost, mulches, combination growing media and bark), plant foods, wetting agents, plant protection products, pesticides,
herbicides, insecticides, fungicides, rodenticides, repellents, bird food, residential outdoor surface cleaners, residential aquatic pest control and related treatments, and durable applicators, through retail channels for end-use by consumers, as
will be further narrowed by the Parties by reference to a combination of certain parameters, such as package size, labeling, advertising, positioning and classification within store, price, and targeted end user, as is customary for such consumer
lawn, garden, and outdoor living products. For purposes of clarity, the “Consumer Market” shall expressly exclude the Ag Market, the Aquatic Market, and the Professional Market. 

  
 2 

 1.3.7    “Declined MBI Technology” shall
have the meaning attributed to it in Section 3.3.3 hereof. 
 1.3.8    “Development
IP” shall mean any improvement, device, prototype, product, active ingredient, formulation, apparatus, system, method, process, invention, know-how, Trade Secret, Confidential Information, or other technical, industrial, or intellectual
property, that is conceived or first reduced to practice during a Development Project under this Agreement and an executed Project Plan, whether protectable or not in the United States or abroad by Intellectual Property Rights; except that
Development IP shall expressly exclude any improvements made anytime by anyone to active ingredient compounds within the Intellectual Property Rights owned or licensed by MBI prior to the Effective Date of this Agreement or outside the scope of any
Development Project if owned or licensed by MBI after the Effective Date of this Agreement. 
 1.3.9 “Development
Project” shall mean any development activities specific to commercialization in the Consumer Market in the Territory that may be required for an MBI Proposed Technology, or, any other collaborative development activities as may be proposed
by the Project Management Committee, if mutually agreed by the Parties, which shall be governed by a corresponding Project Plan that is duly executed on behalf of the Parties. 

1.3.10  “Disputes” shall have the meaning attributed to it in Section 12.8 hereof. 

1.3.11  “Exclusivity Fee” shall have the meaning attributed to it in Section 2.4 hereof. 

1.3.12  “Exclusivity Grant” shall have the meaning attributed to it in Section 2.1 hereof.

 1.3.13  “Exclusivity Period” shall have the meaning attributed to it in Section 2.3
hereof. 
 1.3.14  “Intellectual Property Rights” or “IP Rights” shall mean any
and all: (i) patents, patent applications, copyrights, trademarks, trade names, domain names, goodwill associated with trademarks and trade names, and designs; (ii) rights relating to inventions, innovations, know-how, Trade Secrets, and
confidential, technical, and non-technical information; (iii) moral rights, mask work rights, author’s rights, and rights of publicity; and (iv) other industrial, proprietary, and intellectual property related rights anywhere in the
world, that exist as of the Effective Date or hereafter come into existence, and all applications for, renewals of and extensions of the foregoing, regardless of whether or not such rights have been registered with the appropriate authorities in
such jurisdictions in accordance with the relevant laws. 

  
 3 

 1.3.15 “Joint Development IP” shall have the meaning attributed
to it in Section 8.2.3 hereof. 
 1.3.16 “Legacy Agreement” shall have the meaning attributed to it
in Section 2.6 hereof. 
 1.3.17 “MBI Background IP” shall mean Background IP for which the
Intellectual Property Rights became owned or licensed by MBI prior to the Effective Date of this Agreement, or, outside the scope of any Development Project if after the Effective Date of this Agreement. Further, notwithstanding anything to the
contrary in this Agreement, MBI Background IP shall also include any improvements made anytime by anyone to active ingredient compounds within the Intellectual Property Rights owned or licensed by MBI prior to the Effective Date of this Agreement or
outside the scope of any Development Project if owned or licensed by MBI after the Effective Date of this Agreement. 

1.3.18 “MBI Development IP” shall have the meaning attributed to it in Section 8.2.2 hereof. 

1.3.19 “MBI Proposed Technology” shall have the meaning attributed to it in Section 3.1 hereof. 

1.3.20 “MBI Technology Portfolio” shall mean any and all products or technologies, including but not limited
to any improvement, device, prototype, product, active ingredient, formulation, apparatus, system, method, process, invention, know-how, Trade Secret, Confidential Information, or any other technical, industrial, or intellectual property, and the
Intellectual Property Rights related thereto, owned or controlled by MBI, whether existing as of the Effective Date or otherwise later conceived during the Exclusivity Period, including but not limited to the MBI Background IP. 

1.3.21 “MTA” shall mean that certain Materials Transfer, Confidentiality and Evaluation Agreement dated
May 2, 2011 by and between the Parties. 
 1.3.22 “Professional Market” shall mean the market(s) for
direct or indirect sale or provision of pest control or plant disease management products or services through non-retail channels for end-use by professional service providers in residential and non-residential applications. 

1.3.23 “Project Management Committee” shall have the meaning attributed to it in Section 6.1 hereof.

 1.3.24 “Project Plan” shall mean the specific terms and conditions, as may be agreed upon in writing by
the Parties, that govern a corresponding Development Project, and which shall be incorporated by reference into this Agreement pursuant to Section 1.1 hereof. 

  
 4 

 1.3.25 “Scotts Background IP” shall mean Background IP for
which the Intellectual Property Rights became owned or licensed by Scotts prior to the Effective Date of this Agreement, or, outside the scope of any Development Project if after the Effective Date of this Agreement. 

1.3.26 “Scotts Development IP” shall have the meaning attributed to it in Section 8.2.1 hereof. Scotts
Development IP shall not include improvements to MBI Background IP. 
 1.3.27 “Term” shall have the mean
attributed to it in Section 10.1 hereof. 
 1.3.28 “Territory” shall mean worldwide, except as
prohibited by applicable laws or regulations. 
 1.3.29 “Trade Secret” shall mean: information including,
but not limited to, technical or nontechnical data, a formula pattern, compilation, program, device, method, technique, drawing, process, financial data, or list of actual or potential customers or suppliers which: (i) derives economic value,
actual or potential, from not being generally known to other persons who can obtain economic value from its disclosure or use; and (2) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy or
confidentiality. 
 Article 2. 

EXCLUSIVITY 

2.1    Grant of Exclusivity.  MBI hereby grants to Scotts, and Scotts hereby accepts, a
first and exclusive right, during the Exclusivity Period, to evaluate, develop, and negotiate with MBI for a separate mutually agreeable Commercial Supply and License Agreement with respect to, the MBI Technology Portfolio, for potential
commercialization within the Consumer Market in the Territory, subject to the terms and conditions of this Agreement (the “Exclusivity Grant”). 

2.2    Exclusivity.  During the Exclusivity Period, MBI hereby covenants and agrees that,
except for any Declined MBI Technology, MBI will not grant to a third party any right, during the Exclusivity Period, to evaluate, develop, or negotiate with MBI for any agreement providing rights with respect to, the MBI Technology Portfolio, for
potential commercialization within the Consumer Market in the Territory, nor will MBI assign, license, or otherwise transfer to or for the benefit of a third party any right in or to, or otherwise take any action to encumber, in whole or in part,
the MBI Technology Portfolio, or any Intellectual Property Rights related thereto, to any extent or in any manner that is inconsistent with or in violation of Scotts’ exclusive rights under the Exclusivity Grant; provided, that nothing herein
shall limit MBI’s ability to grant a security interest in any of its property, including the Intellectual Property Rights, in connection with any bank or similar financing. 

  
 5 

 2.3     Exclusivity Period.  Subject to each
Party’s right to terminate pursuant to Section 2.5 hereof and provided that Scotts fully and timely pays MBI the Exclusivity Fee according to the payment schedule pursuant to Section 2.4 hereof, the Exclusivity Period shall run from
the Effective Date for a period of five (5) years (the “Exclusivity Period”). 

2.4     Exclusivity Fee. Subject to each Party’s right to terminate the Exclusivity Period
pursuant to Section 2.5 hereof, and in consideration for the Exclusivity Grant, Scotts shall pay MBI the following payments according to the following schedule and subject to the respective conditions (collectively, the “Exclusivity
Fee”): 
 (a) A first and non-refundable payment in the amount of [*****], to be paid [*****]. 

(b) A second non-refundable payment in the amount of [*****], to be paid [*****] (the “Second Exclusivity Fee
Payment”). 
 (c) A third non-refundable payment in the amount of [*****], to be paid [*****] (the “Third
Exclusivity Fee Payment”). 
 (d) An additional non-refundable payment in the amount of [*****], to be paid upon
the [*****] (the “Commercialization Fee Payment”). For purposes of clarity, no additional payment is due under this Section 2.4 for any subsequent commercialization(s) in the Consumer Market of any additional products or
technologies within the MBI Technology Portfolio. 
 2.5    Early Termination of the Exclusivity
Period. 
 2.5.1    Declined MBI Technologies.    The Exclusivity Period
and the Exclusivity Grant shall automatically terminate with respect to each and every MBI Proposed Technology that becomes a Declined MBI Technology pursuant to Section 3.3.3 hereof. 

2.5.2    Scotts’ Right to Terminate Exclusivity.    Scotts may, at its
sole discretion and for any or no reason (for example, but not limited to, if an MBI Proposed Technology fails to meet Scotts’ efficacy criteria, business model expectations, or other performance or success criteria, etc.), terminate the
Exclusivity Period and the Exclusivity Grant in its entirety, except for any Legacy Agreements, by giving MBI prior written notice that Scotts will not pay the Second Exclusivity Fee Payment and/or the Third Exclusivity Fee Payment and thereby is
terminating the Exclusivity Period and the Exclusivity Grant in its entirety, except for any Legacy Agreements, effective as of the date the first of such payments not paid otherwise would have been due. 

  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 6 

 2.5.3    MBI’s Right to Terminate
Exclusivity.  MBI may terminate the Exclusivity Period and the Exclusivity Grant, in its entirety except for any Legacy Agreements, in the event that Scotts materially defaults in performing any obligation under this Agreement or
otherwise is in breach of any material provision of this Agreement (for example, but not limited to, failure by Scotts to timely make any payment of the Exclusivity Fee), and such default or breach continues unremedied for a period of thirty
(30) days following written notice from MBI to Scotts of such default or breach, such termination being effective as of the end of the thirty (30) day period such default or breach continues unremedied, or if such default or breach is
incapable of cure then such termination shall be immediately effective upon such written notice. During the cure period, if any, neither Party may suspend its performance under this Agreement. 

2.6    Effect of Early Termination or Expiration of Exclusivity Period; Legacy
Agreements.  Unless otherwise agreed in writing by the Parties, and notwithstanding any other provision herein to the contrary, early termination or expiration of the Exclusivity Period and Exclusivity Grant under this Section 2
shall have no impact or effect on the Parties’ rights and obligations regarding exclusivity specifically with respect to any Project Plan or Commercial Supply and License Agreement that is entered into by the Parties pursuant to this Agreement
prior to the date of such early termination or expiration of the Exclusivity Period and Exclusivity Grant (each, a “Legacy Agreement”). Any such Legacy Agreement shall remain in effect and shall continue pursuant to its respective
terms and conditions, and any applicable terms and conditions of this Agreement, including any such terms and conditions regarding exclusivity. Moreover, in the event any such Legacy Agreement results in the first commercialization in the Consumer
Market by Scotts of an herbicide or insecticide as contemplated under Section 2.4(d) hereof, Scotts shall be obligated to pay MBI the Commercialization Fee Payment, notwithstanding the early termination or expiration of the Exclusivity Period
and Exclusivity Grant. 
 Article 3. 

EVALUATION 

3.1    Disclosure of MBI Technology Portfolio; Written Notice of MBI Proposed
Technology(ies).    During the Exclusivity Period, MBI shall give to Scotts written notice, which may be delivered via electronic mail, indicating that a product or technology within the MBI Technology Portfolio has been
determined by MBI to be ready to be commercialized, or is otherwise available for consideration for potential commercialization, in the Consumer Market in the Territory. If MBI, as of the Effective Date, is commercializing (itself or through a third
party) any product or technology within the MBI Technology Portfolio in any of the Ag Market, Aquatic Market, or Professional Market, or, subsequently during the Exclusivity Period, determines to commercialize (itself or through a third party) any
product or technology within the MBI Technology Portfolio in any of the Ag Market, Aquatic Market, or Professional Market, MBI shall give to Scotts written notice, which may be via electronic mail, indicating that such product or technology within
the MBI Technology Portfolio is available for 

  
 7 

 
evaluation by Scotts for potential commercialization in the Consumer Market in the Territory (inclusive of the preceding sentence in this Section 3.1, each such individual product or
technology matter within the MBI Technology Portfolio identified and disclosed to Scotts in writing by MBI under this Section 3.1, an “MBI Proposed Technology”). 

3.2     Evaluation by Scotts.    Scotts shall evaluate each MBI Proposed
Technology for potential commercialization in the Consumer Market in the Territory as provided herein. 

3.2.1  Evaluation under MTA.  The scope and extent of any such evaluation shall be at Scotts’
sole discretion, subject to Scotts’ obligation to provide written notice pursuant to Section 3.3 hereof, and provided that any evaluation by Scotts shall be conducted pursuant to the terms and conditions, including without limitation the
confidentiality provisions, of that certain Materials Transfer, Confidentiality and Evaluation Agreement dated May 2, 2011 by and between the Parties (the “MTA”), which is incorporated herein by reference. 

3.2.2    Cooperation by MBI.  As may be reasonably requested by Scotts, MBI shall
provide Scotts with reasonable assistance and cooperation to facilitate Scotts’ efforts in carrying out any evaluation pursuant to this Section 3.2. To the extent any evaluation by Scotts is delayed as a direct result of a delay by MBI in
providing such reasonable assistance and cooperation after written notice from Scotts detailing its request, Scotts’ obligation to provide written notice pursuant to Section 3.3 hereof shall extend for a period of time commensurate to such
delay, such extension to in no event be for longer than three (3) months. 
 3.3    Scotts’
Written Notice of Interest in Commercializing.  Within [*****] from receiving written notice from MBI regarding an MBI Proposed Technology, which [*****] period may be extended by mutual written agreement of the Parties for a
reasonable period of time to accommodate agronomic requirements or limitations for performing an evaluation pursuant to Section 3.2 hereof, Scotts shall give written notice, which may be delivered via electronic mail, to MBI indicating whether
Scotts has interest, or not, in commercializing such MBI Proposed Technology in the Consumer Market in the Territory, and, if so, whether Scotts believes additional development activities specific to commercialization in the Consumer Market in the
Territory may be required as specified in Article 4 hereof. 
 3.3.1    Additional Development
Required to Commercialize.  If Scotts indicates in such written notice to MBI that Scotts believes additional development activities specific to commercialization in the Consumer Market in the Territory may be required for such MBI
Proposed Technology, the Parties shall determine, via the Project Management Committee, whether or not such additional development is required pursuant to Article 4 hereof. 

  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 8 

 3.3.2    No Additional Development Required to
Commercialize.  If Scotts indicates in such written notice to MBI, or if the Parties otherwise determine pursuant to Article 4 hereof, that no additional development activities specific to commercialization in the Consumer Market in
the Territory are required for such MBI Proposed Technology, the Parties shall proceed with good faith negotiations of a separate mutually agreeable Commercial Supply and License Agreement pursuant to Article 5 hereof. 

3.3.3    No Interest in Commercializing; Declined MBI Technology.  If Scotts indicates
in such written notice that Scotts has no interest in commercializing such MBI Proposed Technology in the Consumer Market in the Territory, or if Scotts fails to timely reply within such [*****] period, then, in each case, such MBI Proposed
Technology shall be deemed declined by Scotts and discharged from the rights and obligations of the Exclusivity Grant (each, a “Declined MBI Technology”), and, effective immediately, the Exclusivity Period and Exclusivity Grant with
respect to such Declined MBI Technology shall terminate, and MBI shall be free to explore the possibility of commercializing any such Declined MBI Technology in the Consumer Market in the Territory with a third party and such Declined MBI Technology
shall be free from further restriction or limitation of any kind under this Agreement or otherwise. 
 Article 4. 

DEVELOPMENT 

4.1    Development Projects under Project Plans.  If Scotts indicates in written notice
to MBI, pursuant to Article 3 hereof, that additional development activities specific to commercialization in the Consumer Market may be required for an MBI Proposed Technology, or, if the Project Management Committee otherwise proposes that the
Parties undertake any other collaborative development activities, the Parties shall determine, via the Project Management Committee, and if mutually agreed then put in writing in a corresponding Project Plan that is duly executed on behalf of the
Parties, the scope and extent of any such development activities that shall be performed as a Development Project under this Agreement. 

4.1.1    Requirements for Project Plans.  The Parties agree that this Agreement provides
the general framework for collaborative development activities between the Parties as one or more Development Projects, and that any special terms for each of such Development Projects shall be set forth in a corresponding Project Plan executed and
delivered by the Parties. 
 4.1.2    Content of Project Plans.  In any Project Plan,
the Parties shall consider including terms addressing the following: 
 (a) a statement of the Parties’ specific
responsibilities, deliverables, and obligations. 
 (b) timelines and milestones for deliverables and obligations. 

(c) the financial and other contributions of the Parties and related operating budgets. 

  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 9 

 (d) the Parties’ respective rights in the output of the Parties’
collaborative development activities. 
 (e) the agreed upon territory. 

(f) the term of the Project Plan and any renewal or termination rights; 

(g) any other terms and conditions that the Parties deem necessary or appropriate with respect to the subject of such Project
Plan. 
 (h) any deviations from the terms of this Agreement. 

4.2        Development Responsibilities.   Each Party shall have
responsibility for all development activities attributed to it under a Development Project in the corresponding Project Plan. 

4.2.1    General Responsibilities - MBI.  Subject at all times to the terms and
conditions of this Agreement and of any specific executed Project Plan, it is anticipated that MBI shall have responsibility under this Agreement and under any executed Project Plan for the following: 

(a) Development of effective and environmentally responsible natural products that focus on unmet needs for weed, pest, and
plant disease management, as well as technologies for the commercially feasible manufacture of such products, that MBI, in its sole discretion, deems suitable for potential commercialization in the Ag Market in one or more countries or regions
within the Territory. 
 (b) Toxicology work and regulatory registrations of active ingredient(s) and final formulation(s)
of all MBI Proposed Technology for the Ag Market. 
 (c) Formulation and stability work of all MBI Proposed Technology for
the Ag Market. 
 (d) Biology / field testing commonly performed for potential commercialization in the Ag Market for all
MBI Proposed Technology. 
 (e) Reasonable support, assistance, and cooperation to facilitate Scotts’ efforts in
carrying out any activities, such as evaluation or development activities, under this Agreement. 
 (f) Any additional
responsibilities in connection with development activities under a Development Project as described in a corresponding Project Plan. 

4.2.2    General Responsibilities - Scotts. Scotts shall have responsibility under this Agreement,
generally, and under any executed Project Plan, specifically, unless expressly and specifically stated otherwise by the Parties in such executed Project Plan, for at least the following: 

(a) All formulation and application work specific to potential commercialization in the Consumer Market of an MBI Proposed
Technology. 
 (b) All toxicology work specific to potential commercialization in the Consumer Market of an MBI Proposed
Technology. 
 (c) All regulatory registration specific to potential commercialization in the Consumer Market of an MBI
Proposed Technology. 
 (d) All biology / field testing specific to potential commercialization in the Consumer Market of an
MBI Proposed Technology. 

  
 10 

 (e) Any additional responsibilities in connection with development activities
under a Development Project as described in a corresponding Project Plan. 
 4.3    Development Costs
and Expenses. 
 4.3.1     Ag Market – Costs Borne by MBI.  Unless otherwise
agreed by the Parties in an applicable executed Project Plan, MBI, at its sole discretion, shall bear any and all costs and expenses in connection with development of an MBI Proposed Technology for potential commercialization in the Ag Market. 

4.3.2    Consumer Market – Costs Borne by Scotts.  Unless otherwise agreed by the
Parties in an applicable executed Project Plan, Scotts shall bear any and all costs and expenses in connection with development of an MBI Proposed Technology for potential commercialization in the Consumer Market. 

4.4    Project Duration.  The duration of any Development Project shall be defined in the
corresponding executed Project Plan. Unless otherwise agreed in writing by the Parties, even upon expiration or termination of the Exclusivity Period pursuant to Article 2 above, any Project Plan executed prior to such early termination or
expiration of the Exclusivity Period shall remain in effect and shall continue pursuant to the terms and conditions of the corresponding Project Plan. 

Article 5. 

COMMERCIALIZATION 

5.1    Commercial Supply and License Agreement.  For any MBI Proposed Technology, which
is not a Declined MBI Technology, for which Scotts indicates in writing to MBI pursuant to Section 3.3 above that Scotts has interest in commercializing in the Consumer Market, the Parties shall proceed, in accordance with the provisions of
this Article 5, in good faith with negotiations of a separate mutually agreeable commercial supply and license agreement under which MBI would supply a suitable form (e.g., a technical grade active ingredient, a final formulation, etc.) of such MBI
Proposed Technology to Scotts for incorporation into a finished product for commercialization by Scotts in the Consumer Market in the Territory on an exclusive basis (each, a “Commercial Supply and License Agreement”). 

5.2    Negotiation Period.  Unless otherwise agreed in writing by the Parties, as part of
a Project Plan or otherwise, the Parties shall proceed in good faith with negotiations of a separate mutually agreeable Commercial Supply and License Agreement in connection with a specific MBI Proposed Technology for a period of no longer than
[*****] from the date of receipt by MBI of the written notice from Scotts pursuant to Section 3.3 above in connection with such MBI Proposed Technology (the “Negotiation Period”). 

  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 11 

 5.3     Supplied Price.  The Parties acknowledge and agree
that, as a term of any separate mutually agreeable Commercial Supply and License Agreement, MBI shall supply a suitable form (e.g., a technical grade active ingredient, a final formulation, etc.) of the subject MBI Proposed Technology to Scotts at a
price that is: (a) [*****]. In determining [*****], the Parties shall consider any available historical price data for comparable product(s) commercialized in the Ag Market and/or Consumer Market, as applicable, [*****]. 

5.4    Exclusivity of Supply and Purchase.  The Parties acknowledge and agree that, as a
term of any separate mutually agreeable Commercial Supply and License Agreement, MBI shall supply a suitable form (e.g., a technical grade active ingredient, final formulation, etc.) of the subject MBI Proposed Technology to Scotts on an exclusive
basis in the Consumer Market for an ongoing period under such Commercial Supply and License Agreement [*****]. Under any Commercial Supply and License Agreement, Scotts will agree to exclusively purchase all of its requirements of the subject MBI
Proposed Technology from MBI. 
 5.5    Other Terms of Commercial Supply and License
Agreement.   The Parties acknowledge and agree that any separate mutually agreeable Commercial Supply and License Agreement may contain certain additional terms and conditions, further to those expressly provided for in this Article 5,
as are customary and appropriate for such an agreement. 
 5.6     Final Approval; Effect of No
Agreement.   If, upon expiration of the Negotiation Period, the Parties have not executed a Commercial Supply and License Agreement with respect to such MBI Proposed Technology, then, in each case, such MBI Proposed Technology shall be
deemed to be a Declined MBI Technology, and, effective immediately, the Exclusivity Period and Exclusivity Grant with respect to such Declined MBI Technology shall terminate, MBI shall be free to explore the possibility of commercializing any such
Declined MBI Technology in the Consumer Market in the Territory with a third party and such Declined MBI Technology shall be free from further restriction or limitation of any kind under this Agreement or otherwise. 

  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 12 

 Article 6. 

GOVERNANCE 

6.1     Project Management Committee.  The Parties shall appoint and maintain a
committee, which shall be comprised of one representative of each Party, as an advisory body to manage the Parties’ collaborative activities under this Agreement and to provide a forum for the Parties to address issues relating to this
Agreement and the activities performed hereunder (the “Project Management Committee”). 

6.2    Meetings.  The Project Management Committee shall meet (telephonically or in
person) periodically, and in any event no less than once per calendar quarter during the Term of this Agreement, to review and discuss the MBI Technology Portfolio and/or each Party’s activities under this Agreement, including but not limited
to any MBI Proposed Technology, the status of any evaluations by Scotts regarding any such MBI Proposed Technology, any Development Projects and/or a need therefor, budgets under any Project Plans and expenditures pursuant to such budgets, and the
like. In addition, the Project Management Committee shall hold special meetings (telephonically or in person) if requested by any member of the Project Management Committee or either Party. 

6.3    Authority.  The Parties agree that the Project Management Committee shall be only
an advisory body and shall have no authority to bind the Parties. The Parties may only waive, modify, or amend this Agreement or any Project Plan by a written instrument duly executed on behalf of the Parties as set forth in Section 12.16
hereof. 
 6.4    Responsibilities.    The Project Management Committee shall
have responsibility for at least the activities identified in this Section 6.4 and its subsections. 

6.4.1    New Development Projects.  The Project Management Committee shall recommend and
advise, pursuant to Article 4 hereof, whether a Development Project shall be established to perform additional development activities specific to commercialization in the Consumer Market in the Territory for an MBI Proposed Technology. Additionally,
the Project Management Committee may propose that the Parties undertake any other collaborative development activities as a Development Project under this Agreement. The details of any Development Project shall be mutually agreed by the Parties and
described in writing in a corresponding Project Plan that is duly executed on behalf of the Parties pursuant to Article 4 hereof. 

6.4.2    Target Range Price Per Unit for the Consumer Market.  Prior to commencement of
work by either Party in connection with any Development Project, the Project Management Committee shall identify a target range for the price per unit of a suitable form (e.g., a technical grade active ingredient, final formulation, etc.) of the
subject MBI Proposed Technology for potential commercialization in the Consumer Market in the Territory, which target range shall be noted in the corresponding Project Plan. In determining any such target range for the price per unit, the Parties
shall consider any available historical price data for comparable product(s) commercialized in the Consumer Market in the Territory. 

  
 13 

 Article 7. 

CONFIDENTIAL INFORMATION 

7.1    Confidential Information.  All information related to this Agreement or MBI’s
or Scotts’ business or products or technologies, written and oral, furnished, directly or indirectly, by a Party (“Discloser”) or the Discloser’s directors, officers, employees, consultants, affiliates, agents or
representatives (collectively, “Representatives”), to the other Party (“Recipient”) or Recipient’s Representatives in connection with this Agreement, including all Project Plans attachments hereto, shall be
considered Discloser’s “Confidential Information”. Notwithstanding the foregoing, the following shall not be considered Discloser’s Confidential Information: (a) information which is or becomes publicly available
other than as a result of a disclosure by Recipient or Recipient’s Representatives, (b) information which is or becomes available to Recipient on a non-confidential basis from a source which, to the best of Recipient’s knowledge after
due inquiry, is not prohibited from disclosing such information to Recipient by a legal, contractual or fiduciary obligation to Discloser, or (c) information which is independently developed by Recipient or Recipient’s Representatives
without use or reference to Discloser’s Confidential Information. Discloser’s Confidential Information shall include all tangible and electronic copies of Discloser’s Confidential Information. Discloser’s Confidential Information
shall not become non-confidential as a result of being included in documents that also contain non-Confidential Information. 

7.2    Non-Disclosure Obligation.  Recipient hereby agrees that Recipient and
Recipient’s Representatives (a) will keep the Discloser’s Confidential Information confidential and will not (except as required by applicable law, regulation or legal process, and only after compliance with Section 7.3 hereof
below), without Discloser’s prior written consent, disclose any of Discloser’s Confidential Information in any manner whatsoever, and (b) will not use any of Discloser’s Confidential Information other than in connection with its
performance and/or obligations under this Agreement. Recipient further agrees to provide access to Discloser’s Confidential Information only to those of Recipient’s Representatives who have a “need to know” such information.
Recipient shall inform all of Recipient’s Representatives who have access to Discloser’s Confidential Information of the confidential nature of the Discloser’s Confidential Information and will cause Recipient’s Representatives
to observe the terms of this Agreement. Recipient hereby agrees to be responsible for any breach of this Agreement by any of Recipient’s Representatives. Either Party may disclose the existence and terms of this Agreement in connection with a
potential acquisition of substantially the entire business of that Party or a private or public offering of either Party’s securities, and each Party may also discuss the terms of this Agreement to its counsel, accountants, directors (including
board observers), and agents in accordance with the terms of this Article 7. 
 7.3    Legally
Compelled Disclosures.  In the event that Recipient or any of its Representatives are requested pursuant to, or required by, applicable law, regulation or legal process to disclose any of the Discloser’s Confidential Information,
Recipient will notify Discloser promptly so that Discloser may seek a protective order or other 

  
 14 

 
appropriate remedy or, in Discloser’s sole discretion, waive compliance with the terms of this Agreement. In the event that no such protective order or other remedy is obtained, or that
Discloser does not waive compliance with the terms of this Agreement, Recipient will furnish only that portion of the Discloser’s Confidential Information which Recipient is advised by counsel is legally required and will exercise all
reasonable efforts to obtain reliable assurance that confidential treatment will be accorded the Discloser’s Confidential Information. 

7.4    Injunctive Relief.    Each Party agrees that if a court of competent
jurisdiction determines that the other Party has breached, or attempted or threatened to breach, its confidentiality obligations to the other Party, the other Party will be entitled to obtain appropriate injunctive relief and other measures
restraining further, attempted or threatened breaches, of such obligations. Such relief or measures shall be in addition to, and not in lieu of, any other rights and remedies available to the other Party. 

7.5    Return of Information.  Discloser may, for any reason, at any time and from time
to time, deliver a written request to Recipient for the return of all, or a portion, of the Discloser’s Confidential Information in the possession of Recipient or Recipient’s Representatives. Upon receiving such written request from
Discloser, (a) Recipient shall promptly destroy or deliver to Discloser (as practical) all of Discloser’s Confidential Information that is the subject of Discloser’s request, and any copies thereof, in Recipient’s or
Recipient’s Representatives’ possession, and (b) neither Recipient nor any of Recipient’s Representatives shall retain any copies thereof. Any oral Confidential Information will continue to be subject to the terms of this
Agreement. 
 Article 8. 

INTELLECTUAL PROPERTY 

8.1    Background IP. 

8.1.1    MBI Background IP.  As between the Parties, MBI owns or retains all right,
title, and interest in the MBI Background IP. 
 8.1.2    Scotts Background
IP.    As between the Parties, Scotts owns or retains all right, title, and interest in the Scotts Background IP. 

8.1.3    Limited License to Scotts.    Subject to the terms and conditions
hereof and the terms and conditions of the MTA, MBI hereby grants to Scotts a limited, non-sublicensable and non-transferable license (or sublicense, as applicable) under the MBI Background IP to the extent necessary for Scotts to perform
evaluations under the terms of this Agreement and the MTA of MBI Proposed Technology and any development activities under a Development Project as detailed in a corresponding executed Project Plan. For purposes of clarity, Scotts shall have no
rights in the MBI Background IP for purposes of commercialization unless and until the Parties enter into a separate mutually agreeable Commercial Supply and License Agreement. The license 

  
 15 

 
granted in this Section 8.1.3 will continue for the Term of this Agreement, or, as to any MBI Proposed Technology that is the subject of an executed Project Plan, the term of such Project
Plan, unless this Agreement, or such Project Plan, is earlier terminated in accordance with Article 10 or otherwise. 

8.1.4    No Other License.  Except as expressly provided herein, and unless otherwise
agreed in writing by the Parties, neither Party grants to the other Party any right or license under or to its respective Background IP. 

8.2    Development IP. 

8.2.1    Ownership by Scotts; License to MBI.  Subject to the terms and conditions
hereof, Scotts shall solely own any and all Development IP that may arise under this Agreement and (A) is derived from solely (i) Scotts Background IP or Scotts’ Confidential Information, or (ii) contributions by one or more of
Scotts’ employees, and (B) is not an improvement to an active ingredient compound within the MBI Background IP (collectively, the “Scotts Development IP); and, subject to negotiation by the Parties of a separate mutually
agreeable reasonable royalty-bearing license agreement, Scotts will grant to MBI an exclusive, reasonable royalty-bearing, worldwide license to such Scotts Development IP, with a right to sublicense, for use solely outside the Consumer Market. For
purposes of clarity, MBI shall have no rights to use any Scotts Development IP outside the Consumer Market or otherwise, unless and until the Parties enter into a separate mutually agreeable licensing agreement under which MBI would pay Scotts a
reasonable royalty for such rights. Further, during the Term of this Agreement, other than to MBI, Scotts shall not grant to a third party any license or right to any Scotts Development IP outside of the Consumer Market, nor shall Scotts itself use
the Scotts Development IP in any market or markets other than the Consumer Market. 

8.2.2    Ownership by MBI.  MBI shall solely own any and all Development IP that may
arise under this Agreement and is derived from solely (i) MBI Background IP or MBI’s Confidential Information, or (ii) contributions by one or more of MBI’s employees (collectively, the “MBI Development IP”); and
all such MBI Development IP immediately and automatically becomes part of the MBI Technology Portfolio and subject to Scotts’ exclusive rights under the Exclusivity Grant. For purposes of clarity, Scotts shall have no rights in the MBI
Development IP for purposes of commercialization unless and until the Parties enter into a separate mutually agreeable Commercial Supply and License Agreement. 

8.2.3    Joint Ownership.  Unless otherwise agreed in a separate written and executed
agreement by the Parties, notwithstanding the provisions of Sections 8.2.1 and 8.2.2 above, the Parties shall jointly own any and all Development IP that may arise under this Agreement and (A) is derived from a combination of (i) Scotts
Background IP or Scotts’ Confidential Information and MBI Background IP or MBI Confidential Information, or (ii) contributions by one or more of Scotts’ employees and contributions by one or more of MBI’s employees, and
(B) is not an improvement to an active ingredient compound within the MBI Background IP (collectively, the “Joint 

  
 16 

 
Development IP”); provided that neither Party shall have any rights in the Joint Development IP for purposes of commercialization (by itself or via any third party) unless and until
the Parties enter into a separate mutually agreeable reasonable royalty-bearing license agreement under which the Parties shall specify rights and obligations as between the Parties with respect to the Joint Development IP. 

8.2.4    Patents; Further Assistance.  Each Party may, at its sole discretion and at its
own expense, file one or more applications for patents directed to its respective Background IP or Development IP. The other Party shall promptly execute and deliver any assignments, descriptions, or other instruments as may be necessary or proper
in the reasonable opinion of the first Party to vest in the first Party title to its respective Background IP or Development IP and to enable the first Party to obtain and maintain the entire right and title to its respective Background IP or
Development IP throughout the world. The other Party shall also render to the first Party, at the first Party’s expense, such assistance as the first Party may reasonably require in the preparation and prosecution of applications for patents in
connection with its respective Development IP, and in any litigation in which the first Party may be involved relating to its respective Background IP or Development IP. For any Joint Development IP, each Party shall confer in good faith with the
other to decide whether and when to file one or more applications for patents directed to the same, select suitable patent counsel, agree upon how costs shall be handled, and the like. For purposes of clarity, in any event, neither Party shall file
an application for patent directed to any Joint Development IP without providing thirty (30) days prior written notice to the other Party. Each Party shall promptly execute and deliver any assignments, descriptions, or other instruments as may
be necessary or proper in the reasonable opinion of either Party to vest in each Party joint title to the Joint Development IP and to enable each Party to obtain and maintain the entire joint right and title to the Joint Development IP throughout
the world. 
 Article 9. 

REPRESENTATIONS AND WARRANTIES; DISCLAIMER 

9.1    Representations.  Each Party represents, warrants and covenants to the other that:
(a) it has the full power and authority to enter into and fully perform this Agreement; (b) it has sufficient right and authority to grant all licenses and rights granted or agreed to be granted by it hereunder to the other Party; and
(c) at all times, it will comply with all applicable material international, federal, national, state, provincial, and local laws, treaties, directives, and/or regulations. 

9.2    Disclaimer of Other Warranties.  THE WARRANTIES SET FORTH IN THIS AGREEMENT
AND IN ANY EXECUTED PROJECT PLAN, IF ANY, ARE THE EXCLUSIVE WARRANTIES AND ARE IN LIEU OF ALL OTHER WARRANTIES, AND NEITHER MBI NOR SCOTTS MAKES ANY OTHER WARRANTIES, EXPRESS OR IMPLIED OR STATUTORY, INCLUDING WARRANTIES OF MERCHANTABILITY,
NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE, PERFORMANCE, NONINTERRUPTION OF 

  
 17 

 
OPERATION, OR RESULTS WHICH MAY BE OBTAINED FROM ANY ACTIVITY HEREUNDER. MBI ASSUMES NO RESPONSIBILITIES WHATSOEVER WITH RESPECT TO THE USE, SALE OR OTHER DISPOSITION BY SCOTTS OF ANY PRODUCTS OR
TECHNOLOGY. 
 9.3    LIMITATION OF LIABILITY.    EXCEPT FOR (A) BREACH
BY EITHER PARTY OF ARTICLE 7 (CONFIDENTIALITY) OR BREACH BY EITHER PARTY OF ARTICLE 8 (INTELLECTUAL PROPERTY), OR (B) IN CONNECTION WITH ANY INFRINGEMENT OR MISAPPROPRIATION OF THE INTELLECTUAL PROPERTY OF A PARTY BY THE OTHER PARTY, TO THE
MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT AND UNDER NO LEGAL THEORY IN TORT (INCLUDING NEGLIGENCE), CONTRACT, OR OTHERWISE, INCLUDING ANY EQUITABLE THEORY, SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS OR
REVENUES OR FOR ANY INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL OR PUNITIVE DAMAGES, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER ARISING UNDER, OUT OF, IN RELATION TO, OR IN CONNECTION WITH THIS AGREEMENT OR
ANY PROJECT PLAN, OR ITS NEGOTIATION, PERFORMANCE, TERMINATION, OR ANY OTHER MEANS, AND REGARDLESS OF THE FORM OF ACTION UPON WHICH A CLAIM FOR SUCH DAMAGES MAY BE BASED. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, BOTH PARTIES AGREE THAT IF
ANY REMEDY HEREUNDER IS DETERMINED TO HAVE FAILED OF ITS ESSENTIAL PURPOSE, ALL LIMITATIONS OF LIABILITY AND EXCLUSION OF DAMAGES SET FORTH HEREIN SHALL REMAIN IN EFFECT. 

Article 10. 
 TERM AND
TERMINATION 
 10.1    Term.  The term of this Agreement shall commence on the
Effective Date and continue until the earlier of: (a) the termination or expiration of the Exclusivity Period, or (b) the termination or expiration of this Agreement in accordance with this Article 10 (the “Term”). The
Parties may extend the Term on terms mutually agreed upon in writing by the Parties. The provisions of Articles 7, 8, 9, 10, 11 and 12 of this Agreement shall survive the termination or expiration of this Agreement to the extent applicable to any
executed Project Plans the terms of which extend beyond the termination or expiration date of this Agreement. 

10.2    Termination Upon Default or Breach.  Either Party may terminate this Agreement in
the event that the other Party materially defaults in performing any obligation under this Agreement or otherwise is in breach of any material provision of this Agreement and such default or breach continues unremedied for a period of thirty
(30) days following written notice of such default or breach, such termination being effective as of the end of the thirty (30) day period if such default or breach continues unremedied, or, in the event that the other Party materially
defaults or breaches this Agreement in a manner that is incapable of cure, then this Agreement will automatically 

  
 18 

 
terminate upon notice from the non-defaulting, non-breaching Party. During a cure period, if any, neither Party may suspend its performance under this Agreement. 

10.3    Termination Upon Insolvency.    Either Party may terminate this
Agreement: (a) upon the institution of insolvency, receivership of bankruptcy proceedings or any other proceedings for the settlement of debts of the other Party; (b) upon the making of an assignment for the benefit of creditors by the
other Party; or (c) upon the dissolution of the other Party. 
 Article 11. 

INDEMNIFICATION 

11.1    Indemnity for MBI; Product Liability.    Scotts shall indemnify, hold
harmless and defend MBI, its affiliates and subsidiaries, and its and their respective employees, officers, and directors from and against any and all liabilities, losses, claims, judgments, assessments, obligations, penalties, damages, costs, and
expenses (including reasonably incurred attorneys’ fees) (collectively, “Damages”), resulting from, or arising out of (i) Scotts’ material breach of any of its duties or obligations under this Agreement, and/or
(ii) the willful misconduct of Scotts, its employees, or agents in the performance of Scotts’ duties and obligations, including its representations and warranties, under this Agreement. Scotts shall also indemnify, hold harmless and defend
MBI, its affiliates and subsidiaries, and its and their respective employees, officers and directors from and against any and all Damages suffered by Scotts, or purchasers or users of any products sold by or for Scotts, or any other party, resulting
from, or arising out of, personal injury, death, or property damage related to the manufacture, use, sale or import of such products in the Consumer Market (“Product Liability”), but only to the extent such Damages are not expressly within
the MBI Product Liability Indemnity (as defined below). 
 11.2    Indemnity for Scotts; Product
Liability.    MBI shall indemnify, hold harmless and defend Scotts, its affiliates and subsidiaries, and its and their respective employees, officers and directors from and against any and all Damages resulting from or
arising out of (i) MBI’s material breach of any of its duties or obligations under this Agreement, (ii) the willful misconduct of MBI, its employees or agents in the performance of MBI duties or obligations, including its
representations and warranties, under this Agreement, and/or (iii) a claim of infringement by MBI’s IP Rights of a valid third party patent, trade secret, or other intellectual property right to the extent such claim is based solely upon
Scotts’ use of MBI Proposed Technology in compliance with this Agreement (and not with any IP Rights of Scotts or any third party); provided that nothing in this Agreement shall limit MBI’s ability to enter into any license or other
agreement as necessary to make any MBI IP Rights non-infringing or modify any IP Rights so as to be non-infringing (and to replace any such otherwise used hereunder). MBI shall also indemnify, hold harmless and defend Scotts, its affiliates and
subsidiaries, and its and their respective employees, officers and directors from and against any and all Damages resulting from, or arising out of Product Liability claims, but only to the extent such Damages are attributable to MBI Proposed
Technology used in accordance with the 

  
 19 

 
terms and conditions of any applicable Commercial Supply and License Agreement and such Damages could not have been avoided by the use of such MBI Proposed Technology in unmodified form or
without combination with other technologies or compounds (the “MBI Product Liability Indemnity”). 

11.3    Notice.    In any action covered by the above indemnifications, and to
obtain indemnification from the other Party under this Article 11, the Party requesting indemnification must: (i) notify the indemnifying Party in writing promptly after the Party requesting indemnification receives notice of the claim or
allegation; (ii) allow the indemnifying Party to have sole control of the defense and all related settlement negotiations; and (iii) provide the indemnifying Party with reasonable assistance, information and authority as necessary to
perform its obligations under this Article 11. The indemnifying Party may direct the defense by counsel of its own choice, and the Party requesting indemnification shall be given the opportunity to participate in such defense, and to be
represented by counsel of its own choice and to direct its own defense, but in such case, it shall bear its own counsel fees and expenses. 

11.4    Exception to Indemnity. The indemnity provisions of this Article 11, and the obligations to
provide indemnification hereunder, shall not apply to the extent that the Party requesting indemnification is at fault or the claims at issue are or reasonably likely to be less than [*****]. The indemnity provisions of this Article 11 shall survive
any termination of this Agreement. 
 Article 12. 

MISCELLANEOUS PROVISIONS 

12.1    Survival.  The provisions of Sections 2.4(d), 2.6 and 10.1 and Articles 7, 8, 9,
11, and 12 shall survive termination of this Agreement. All other rights and obligations of the Parties shall cease upon termination of this Agreement. 

12.2    Relationship of Parties.  This Agreement does not create, and shall not be deemed
to create, a partnership, joint venture, agency or any similar relationship or arrangement between the Parties hereto. In carrying out its duties and performing its obligations hereunder, each of the Parties hereto is acting as an independent
contractor, and the employees, subcontractors, agents, or other representatives of one of them shall not be deemed to be employees, subcontractors, agents, or other representatives of the other. 

12.3    Publicity.  Upon execution of this Agreement or any Project Plan hereunder, and
from time to time with each Party’s consent, the Parties shall issue a mutually agreed upon press release or other promotion describing the general nature of such agreement(s) between or activities by the Parties. These shall include joint
announcements on discovery and commercialization and joint presentations at company or industry events. Otherwise, neither Party may make public use of the other Party’s name, proprietary marks, product names, or otherwise refer to or identify
the other Party, 

  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 20 

 
or its divisions and/or subsidiaries, in any advertising, publicity releases, or promotional or marketing correspondence, except to the extent required by law and except as provided in Article 7
above, without securing the prior written consent of such other Party. 

12.4    Counterparts.    This Agreement may be executed in any number of
counterparts, all of which constitute one and the same instrument, and any Party may execute this Agreement by signing and delivering one or more counterparts. 

12.5    Assignment.  Neither Party may, by operation of law or otherwise, assign,
sublicense, or otherwise transfer any of its right or obligations under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld. Notwithstanding the preceding, either Party may assign,
transfer, or otherwise delegate all of its rights and obligations under this Agreement to any successor in interest or purchaser of all or substantially all of its assets, provided that the assignor undertakes to inform in writing the other Party as
soon as reasonably possible. Any prohibited assignment, sublicense, or transfer shall be null and void. This Agreement shall bind, benefit, and be enforceable by and against both Parties and their respective successors and permitted assigns. 

12.6    Notices.  Except as expressly provided otherwise in this Agreement, all notices,
consents, and other communications required or permitted under this Agreement shall be in writing and sent via courier, postage prepaid, with a soft copy via electronic mail or transmitted by facsimile transmission, to the address specified below,
or such other address as either Party may indicate by notice to the other Party: 
  

			
	 If to Scotts:
	  	 If to MBI:

		
	 Steve Titko

Vice President
 Global R&D
Outdoor Living
  
 The Scotts Company LLC

14111 Scottslawn Road
 Marysville,
Ohio 43041, U.S.A.
  
 [*****]
	  	 Pamela G. Marrone

Founder & CEO
  

Marrone Bio Innovations, Inc.

2121 Second Street, Suite 107B

Davis, California 95618, U.S.A.
  

PHONE 530-750-2800
 FAX
530-750-2808
 [*****]

 12.7    Applicable Law.  This Agreement shall be governed
by the internal substantive laws of the State of Delaware, United States of America, without regard to conflict of laws principles. 

12.8    Disputes.  Other than as provided in Article 2 or Article 10, any and all
disputes arising under, out of, or in relation to this Agreement, its formation, performance or termination (“Disputes”) shall initially be referred to the Project Management 

  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 21 

 
Committee. If the Project Management Committee cannot resolve a Dispute within thirty (30) days of referral, the Dispute shall be referred to senior management from both Parties, who shall
meet and attempt to resolve the Dispute. If the Dispute has still not been resolved within fourteen (14) days of such referral, either Party may institute legal proceedings in accordance with Sections 12.7, 12.9, and 12.10 hereof. Other than as
provided in Article 2 or Article 10, the dispute resolution procedure set forth in this Section 12.8 is mandatory, and neither Party shall institute legal proceedings until it has been exhausted, provided, that either Party may resort to court
action for injunctive relief at any time if, in such Party’s good faith belief, the delay associated with the dispute resolution processes set forth in this Section 12.8 would permit or cause irreparable injury to such Party or any third
party claiming against such Party. 
 12.9    Jurisdiction and
Venue.    Disputes that have not been resolved in accordance with the Section 12.8 hereof shall be finally and conclusively determined by a bench trial in a state or federal court sitting in the State of Delaware. MBI
and Scotts expressly consent and submit to the personal jurisdiction of any state or federal court sitting in the State of Delaware. Both Parties further consent, submit to, and agree that venue in any such suit, action, proceeding, or claim is
proper in said court and further expressly waive any and all personal rights under applicable law or in equity to object to the jurisdiction and venue of said court. MBI and Scotts hereby irrevocably waive, to the fullest extent permitted by
applicable law, any and all right such Party has to a trial by jury in any litigation between them arising under, out of, or in relation to this Agreement, its formation, performance, or termination. 

12.10    Attorneys’ Fees.  If any legal action is necessary to enforce the terms of
this Agreement, the prevailing Party will be entitled to reasonable attorneys’ fees, costs, and expenses in addition to any other relief to which such prevailing Party may be entitled. 

12.11    No Waiver.  The failure by a Party to exercise any right hereunder shall not
operate as a waiver of such Party’s right to exercise such right or any other right in the future. No waiver of any breach of this Agreement shall constitute a waiver of any other breach of the same or other provisions of this Agreement, and no
waiver shall be effective unless made in writing and signed by an authorized representative of the Party waiving the breach. 

12.12    Force Majeure.  Neither Party shall be considered in default or incur any
liability hereunder due to any material failure in its performance of this Agreement should such failure arise out of causes beyond its control, including, without limitation, work stoppages, fires, riots, accidents, floods, storms, or failures of
communications or software. The time for performance shall be extended for a period equal to the duration of the conditions preventing performance; provided, however, that such extension may not exceed thirty (30) days without the written
consent of the performing Party. In such event, after the 30-day window or such other longer term as may be agreed between the Parties, the performing Party may terminate this Agreement upon written notice to the non-performing Party. 

  
 22 

 12.13    Severability.  Each of the
covenants of the Parties contained in this Agreement shall be deemed and shall be construed as a separate and independent covenant and should any provision of any such covenants be held or declared invalid, illegal or unenforceable by any court of
competent jurisdiction, such invalidity, illegality, or unenforceability shall in no way render invalid or unenforceable any other part or provision thereof or any other covenant of the Parties not held or declared invalid, and this Agreement shall
be construed as if such invalid, illegal, or unenforceable provision were not contained herein. Furthermore, it is the intention of the Parties hereto that such provision determined to be illegal, invalid, or otherwise unenforceable, to the
extent possible, shall be reformed and construed in a manner which would be valid and enforceable to the maximum extent of the law. 

12.14    Section Headings; Attachments.    The section and subsection headings
used herein are for reference and convenience only, and shall not affect the interpretation hereof. 

12.15    Third Party Beneficiaries.  This Agreement and the rights and obligations
created under it shall be binding upon and inure solely to the benefit of the Parties hereto and their respective successors and permitted assigns, and nothing in this Agreement, express or implied, is intended or should be construed to confer upon
any other person any right, remedy or claim under or by virtue of this Agreement. 
 12.16    Entire
Agreement; Amendment and Waiver.    Each Party acknowledges that it has read this Agreement, understands it, and agrees to be bound by its terms, and further agrees that this Agreement, any Project Plans, and the MTA, each of
which are incorporated herein, constitute the complete and exclusive statement of the agreement between the Parties and supersedes and merges all prior proposals, understandings, and all other agreements, oral and written, between the Parties
relating to the subject matter of this Agreement. No purchase order, or other ordering or confirming document or any handwritten or typewritten text issued by either Party which purports to modify or supplement the text of this Agreement shall add
to or vary the terms of this Agreement. This Agreement may not be modified or altered, and its terms may not be waived, except by a written instrument duly executed on behalf of the Parties (or, in the case of waiver, by the Party against whom such
waiver is to be enforced). 
 [Signatures Appear on the Following Page] 

  
 23 

 IN WITNESS WHEREOF, the Parties have caused this Technology Evaluation and
Master Development Agreement to be duly executed by their respective officers duly authorized therefor and to be effective as of the Effective Date. 
  

			
	 SCOTTS:

	
	 The Scotts Company LLC

		
	 By: 
	 	 /s/ Steve Titko

			
		
	 Name:
	 	 Steve Titko

			
		
	 Title:
	 	 V.P. Global Innovation

  

			
	 MBI:

	
	 Marrone Bio Innovations, Inc.

		
	 By: 
	 	 /s/ Pam Marrone

			
		
	 Name:
	 	 Pamela G. Marrone

			
		
	 Title:
	 	 CEO & Founder

  
 24EX-10.51

 Exhibit 10.51 
 VANDA PHARMACEUTICALS INC. 

EMPLOYMENT AGREEMENT 
 This Employment Agreement (this “Agreement”) was entered into as of April 15, 2013, by and between Paolo Baroldi (the “Executive”) and VANDA
PHARMACEUTICALS INC., a Delaware corporation (the “Company”). 
 1. Duties and
Scope of Employment. 
 (a) Position. For the term of his employment under this Agreement (“Employment”),
the Company agrees to employ the Executive in the position of Senior Vice President, Chief Medical Officer. The Executive shall be subject to the supervision of, and shall have such authority as is delegated to him by, the Company’s Chief
Executive Officer. The Executive hereby accepts such employment and agrees to undertake the duties and responsibilities normally inherent in such position and such other duties and responsibilities as the Company’s Chief Executive Officer shall
from time to time reasonably assign to him. 
 (b) Obligations to the Company. During the term of his Employment, the
Executive shall devote his full business efforts and time to the Company. During the term of his Employment, without the prior written approval of the Company’s Board of Directors (the “Board”), the Executive shall not render services
in any capacity to any other person or entity and shall not act as a sole proprietor or partner of any other person or entity or as a shareholder owning more than five percent of the voting power of any other entity. The Executive shall comply with
the Company’s policies and rules, as they may be in effect from time to time during the term of his Employment. 
 (c)
No Conflicting Obligations. The Executive represents and warrants to the Company that he is under no obligations or commitments, whether contractual or otherwise, that are inconsistent with his obligations under this Agreement. The Executive
represents and warrants that he will not use or disclose, in connection with his Employment, any trade secrets or other proprietary information or intellectual property in which the Executive or any other person has any right, title or interest and
that his Employment as contemplated by this Agreement will not infringe or violate the rights of any other person or entity. The Executive represents and warrants to the Company that he has returned all property and confidential information
belonging to any prior employers. 
 2. Cash and Incentive Compensation. 

(a) Salary. The Company shall pay the Executive as compensation for his services a base salary at a gross annual rate of not less
than $320,000. Such salary shall be payable in accordance with the Company’s standard payroll procedures. (The annual compensation specified in this Subsection (a), together with any increases in such compensation that the Company may
grant from time to time, is referred to in this Agreement as “Base Compensation.”) 

 (b) Incentive Bonuses. The Executive shall be eligible for an
annual incentive bonus with a target amount equal to 40% of his Base Compensation (the “Annual Target Bonus”). Such bonus (if any) shall be awarded based on objective or subjective criteria established in advance by the Board or the
Compensation Committee of the Board (the “Compensation Committee”). Any bonus for the fiscal year in which Executive’s employment begins shall be prorated, based on the number of days Executive is employed by the Company during that
fiscal year. Any incentive bonus for a fiscal year shall in no event be paid later than 2 1/2 months after the close of such fiscal year. Except as provided in Section 6, such bonus shall be paid only if
Executive is employed by the Company at the time of payment. The determinations of the Board or the Compensation Committee with respect to such bonus shall be final and binding. 

(c) Stock Options. On the date of this Agreement, the Company shall grant the Executive a nonstatutory stock option to purchase
150,000 shares of the Company’s Common Stock (the “Option”). The per-share exercise price of the Option shall be equal to the closing price of one share of the Company’s Common Stock on the date of grant as reported on the NASDAQ
Global Market. The maximum term of the Option shall be 10 years, subject to earlier expiration in the event of the termination of the Executive’s service with the Company. The grant of the Option shall be subject to the terms and conditions set
forth in the Vanda Pharmaceuticals Inc. 2006 Equity Incentive Plan and in the Company’s standard form of Stock Option Agreement. The Option will become exercisable with respect to 25% of the shares on the first anniversary of the date of this
Agreement and with respect to the remaining 75% of the shares in equal monthly installments over the next 3 years of continuous service thereafter. The Option shall become exercisable in full if (i) the Company is subject to a Change in Control
before the Executive’s service with the Company terminates and (ii) the Executive is subject to an Involuntary Termination within 24 months after such Change in Control. In addition, Section 6(d) shall apply to the Option. 

(d) Restricted Stock Units. On the date of this Agreement, the Company shall award the Executive restricted stock units covering
50,000 shares of the Company’s Common Stock (the “RSU Award”). The RSU Award shall be subject to the terms and conditions set forth in the Vanda Pharmaceuticals Inc. 2006 Equity Incentive Plan and in the Company’s standard form
of Restricted Stock Unit Award Agreement. The RSU Award will vest with respect to 25% of the shares on January 1, 2014, an additional 25% of the shares on January 1, 2015, an additional 25% of the shares on January 1, 2016, and the
final 25% of the shares on January 1, 2017, provided that Executive’s remains in continuous service with the Company on each applicable vesting date. The RSU Award shall vest in full if (i) the Company is subject to a Change in
Control before the Executive’s service with the Company terminates and (ii) the Executive is subject to an Involuntary Termination within 24 months after such Change in Control. 

3. Vacation and Employee Benefits. During the term of his Employment, the Executive shall be eligible for 25 paid vacation days
each year. Vacation days shall accrue, and may be taken, in accordance with the Company’s standard policy for similarly situated employees, as it may be amended from time to time. During the term of his Employment, the Executive shall be
eligible to participate in any employee benefit plans maintained by the 

  
 2 

 
Company for similarly situated employees, subject in each case to the generally applicable terms and conditions of the plan in question and to the determinations of any person or committee
administering such plan. 
 4. Business Expenses. During the term of his Employment, the Executive shall be authorized to
incur necessary and reasonable travel, entertainment and other business expenses in connection with his duties hereunder. The Company shall reimburse the Executive for such expenses upon presentation of an itemized account and appropriate supporting
documentation, all in accordance with the Company’s generally applicable policies. Any reimbursement shall (a) be paid promptly but not later than the last day of the calendar year following the year in which the expense was incurred,
(b) not be affected by any other expenses that are eligible for reimbursement in any calendar year and (c) not be subject to liquidation or exchange for another benefit. 

5. Term of Employment. 
 (a) Employment at Will. The Executive’s Employment with the Company shall be “at will,” meaning that either the Executive or the Company may terminate the Executive’s Employment
at any time and for any reason, with or without Cause. Any contrary representations which may have been made to the Executive shall be superseded by this Agreement. This Agreement shall constitute the full and complete agreement between the
Executive and the Company on the “at will” nature of the Executive’s Employment, which may only be changed in an express written agreement signed by the Executive and a duly authorized officer of the Company (other than the
Executive). The termination of Executive’s Employment shall not limit or otherwise affect his obligations under Section 7 below. 
 (b) Termination. The Company may terminate the Executive’s Employment at any time and for any reason (or no reason), and with or without Cause, by giving the Executive notice in writing. The
Executive may terminate his Employment by giving the Company 14 days’ advance notice in writing. The Executive’s Employment shall terminate automatically in the event of his death. 

(c) Rights Upon Termination. Except as expressly provided in Section 6, upon the termination of the Executive’s
Employment pursuant to this Section 5, the Executive shall only be entitled to the compensation, benefits and expense reimbursements described in Sections 2, 3 and 4 for the period preceding the effective date of the termination. The
payments under this Agreement shall fully discharge all responsibilities of the Company to the Executive. 
 6. Termination
Benefits. 
 (a) Preconditions. Any other provision of this Agreement notwithstanding, the remaining
Subsections of this Section 6 shall not apply unless each of the following requirements is satisfied: 

(i) The Executive has executed a general release of all known and unknown claims that the Executive may then have against
the Company or persons affiliated with the Company in a form prescribed by the Company, without alterations. The Executive shall execute and return the release on or before the date specified by the Company in the prescribed form (the “Release
Deadline”). The Release Deadline shall in no event be later than 50 days after the Executive’s Separation. If the Executive fails to return the release on or before the Release Deadline, or if the Executive revokes the release, then the
Executive shall not be entitled to the benefits described in this Section 6. 
 (ii) The Executive has
returned all property of the Company in the Executive’s possession. 

  
 3 

 (b) Severance Pay. If, during the term of this Agreement, a Separation occurs because
the Company terminates the Executive’s Employment for any reason other than Cause or Permanent Disability, or because the Executive terminates his Employment within six months after a condition constituting Good Reason arises, then the Company
shall pay the Executive both of the following: 
 (i) Base Compensation. His Base Compensation for a
period of 12 months following the Separation (the “Continuation Period”). Such severance payment shall be paid at the Base Compensation rate in effect at the time of the Separation and in accordance with the Company’s standard payroll
procedures. The severance payments shall commence within 60 days after the Executive’s Separation and, once they commence (the “Payment Commencement”), shall include any unpaid amounts accrued from the date of the Employee’s
Separation. However, if the 60-day period described in the preceding sentence spans two calendar years, then the Payment Commencement shall in any event begin in the second calendar year. 

(ii) Target Bonus. An amount equal to his Annual Target Bonus at the rate in effect at the time of the Separation.
Such amount shall be payable in a lump sum on the Company’s next regularly scheduled payroll that occurs following the Payment Commencement. 
 (c) Health Insurance. If Subsection (b) above applies, and if the Executive elects to continue his health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act
(“COBRA”) following the Separation, then the Company shall pay the Executive’s monthly premium under COBRA until the earliest of (i) the close of the Continuation Period, (ii) the expiration of the Executive’s
continuation coverage under COBRA and (iii) the date when the Executive is offered substantially equivalent health insurance coverage in connection with new employment or self-employment. 

(d) Options. If, during the term of this Agreement, a Separation occurs because the Company terminates the Executive’s
Employment for any reason other than Cause or Permanent Disability, then (i) the vested portion of the shares of the Company’s Common Stock subject to all options held by the Executive at the time of his Separation shall be

  
 4 

 
determined by adding three months to the actual period of service that he has completed with the Company and (ii) such options shall be exercisable for six months after the Executive’s
Separation. 
 7. Non-Solicitation, Non-Disclosure and Non-Competition. The Executive has entered into a Proprietary
Information and Inventions Agreement with the Company, which agreement is incorporated herein by reference. 
 8.
Successors. 
 (a) Company’s Successors. This Agreement shall be binding upon any successor (whether direct
or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets. For all purposes under this Agreement, the term “Company” shall include
any successor to the Company’s business and/or assets which becomes bound by this Agreement. 
 (b) Executive’s
Successors. This Agreement and all rights of the Executive hereunder shall inure to the benefit of, and be enforceable by, the Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees,
devisees and legatees. 
 9. Definitions. For all purposes under this Agreement: 

“Cause” shall mean: 
 (a) An unauthorized use or disclosure by the Executive of the Company’s confidential information or trade secrets, which use or disclosure causes material harm to the Company; 

(b) A material breach by the Executive of any agreement between the Executive and the Company; 

(c) A material failure by the Executive to comply with the Company’s written policies or rules; 

(d) The Executive’s conviction of, or plea of “guilty” or “no contest” to, a felony under the laws of the United
States or any State thereof; 
 (e) The Executive’s gross negligence or willful misconduct; 

(f) A continuing failure by the Executive to perform assigned duties after receiving written notification of such failure from the Board;
or 
 (g) A failure by the Executive to cooperate in good faith with a governmental or internal investigation of the Company or
its directors, officers or employees, if the Company has requested the Executive’s cooperation. 

  
 5 

 “Change in Control” shall mean: 

(a) The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if
persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization 50% or more of the voting power of the outstanding
securities of each of (i) the continuing or surviving entity and (ii) any direct or indirect parent corporation of such continuing or surviving entity; 
 (b) The sale, transfer or other disposition of all or substantially all of the Company’s assets; 
 (c) A change in the composition of the Board, as a result of which fewer than 50% of the incumbent directors are directors who either: 

(i) Had been directors of the Company on the date 24 months prior to the date of such change in the composition of the
Board (the “Original Directors”); or 
 (ii) Were appointed to the Board, or nominated for election to
the Board, with the affirmative votes of at least a majority of the aggregate of (A) the Original Directors who were in office at the time of their appointment or nomination and (B) the directors whose appointment or nomination was
previously approved in a manner consistent with this Paragraph (ii); or 
 (d) Any transaction as a result of which any
person is the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), directly or indirectly, of securities of the Company representing at least 50% of the
total voting power represented by the Company’s then outstanding voting securities. For purposes of this Subsection (d), the term “person” shall have the same meaning as when used in Sections 13(d) and 14(d) of the
Exchange Act but shall exclude (i) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a parent or subsidiary of the Company and (ii) a corporation owned directly or indirectly by the
stockholders of the Company in substantially the same proportions as their ownership of the Common Stock of the Company. 
 A
transaction shall not constitute a Change in Control if its sole purpose is to change the State of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the
Company’s securities immediately before such transaction. 
 “Code” shall mean the Internal Revenue Code
of 1986, as amended. 
 “Good Reason” shall mean (i) a change in the Executive’s position with the
Company that materially reduces his level of authority or responsibility, (ii) a material reduction in his Base Compensation or (iii) receipt of notice that his principal workplace will be

  
 6 

 
relocated by more than 30 miles. A condition shall not be considered “Good Reason” unless the Executive gives the Company written notice of such condition within 90 days after the
initial existence of such condition and the Company fails to remedy such condition within 30 days after receiving the Executive’s written notice. 
 “Involuntary Termination” shall mean a Separation resulting from either (i) the Executive’s involuntary discharge by the Company for reasons other than Cause or (ii) the
Executive’s voluntary resignation for Good Reason. 
 “Permanent Disability” shall mean the
Executive’s inability to perform the essential functions of the Executive’s position, with or without reasonable accommodation, for a period of at least 120 consecutive days because of a physical or mental impairment. 

“Separation” shall mean a “separation from service,” as defined in the regulations under Section 409A of
the Code. 
 10. Miscellaneous Provisions. 
 (a) Notice. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by overnight
courier, U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of the Executive, mailed notices shall be addressed to him at the home address that he most recently communicated to the Company in writing. In the
case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary. 
 (b) Modifications and Waivers. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by the
Executive and by an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any
other condition or provision or of the same condition or provision at another time. 
 (c) Whole Agreement. No other
agreements, representations or understandings (whether oral or written and whether express or implied) which are not expressly set forth in this Agreement have been made or entered into by either party with respect to the subject matter hereof. This
Agreement and the Proprietary Information and Inventions Agreement contain the entire understanding of the parties with respect to the subject matter hereof. 

  
 7 

 (d) Tax Matters. All payments made under this Agreement shall be subject to reduction
to reflect taxes or other charges required to be withheld by law. For purposes of Section 409A of the Code, each periodic salary continuation payment under Section 6(b) is hereby designated as a separate payment. If the Company determines
that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code and the regulations thereunder at the time of his Separation, then: 

(i) Any salary continuation payments under Section 6(b)(i), to the extent not exempt from Section 409A of the
Code, shall commence with the Company’s first regularly scheduled payroll that occurs during the seventh month after the Executive’s Separation and, once such payments commence, any amounts accrued from the Separation date shall be paid in
a lump sum on the first payment date; and 
 (ii) Any lump-sum payment under Section 6(b)(ii) or
Section 6(c), to the extent not exempt from Section 409A of the Code, shall be made with the Company’s first regularly scheduled payroll that occurs during the seventh month after the Executive’s Separation. 

The Company shall not have a duty to design its compensation policies in a manner that minimizes the Executive’s tax liabilities, and the Executive
shall not make any claim against the Company or the Board related to tax liabilities arising from the Executive’s compensation. 
 (e) Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the District of Columbia (except its provisions governing the choice
of law). 
 (f) Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall
not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. 
 (g)
No Assignment. This Agreement and all rights and obligations of the Executive hereunder are personal to the Executive and may not be transferred or assigned by the Executive at any time. The Company may assign its rights under this Agreement
to any entity that assumes the Company’s obligations hereunder in connection with any sale or transfer of all or a substantial portion of the Company’s assets to such entity. 

(h) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
 [REMAINDER OF PAGE LEFT BLANK INTENTIONALLY]

  
 8 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of
the Company by its duly authorized officer, as of the date first written above. 
  

			
	 /s/ Paolo Baroldi

	Paolo Baroldi
	
	VANDA PHARMACEUTICALS INC.
		
	By	 	 /s/ Mihael H. Polymeropoulos, M.D.

		
	Title:	 	 President and Chief Executive Officer

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]